Financial Report: Abbott

Abbott

4Q Revenues: $10.4 billion (+4%)

4Q Earnings: $1.6 billion (+12%)

FY Revenues: $38.9 billion (+11%)

FY Earnings: $4.7 billion (+2%)

Comments: Proprietary Pharmaceutical sales in the quarter were $4.8 billion (+7%), and for the year grew 11% to $17.0 billion. Humira sales were $2.2 billion in the quarter (+16%), and $7.9 billion for the year (+21%). Trilipix/TriCor sales were down 4% to $483 million in the quarter and up 6% to $1.7 billion for the year. Kaletra sales were down 16% to $288 million in the quarter and down 7% to $1.2 billion for the year. Niaspan sales were down 10% to $258 million in the quarter and up 5% to $976 million for the year. Nutritionals sales were $1.6 billion in the quarter and $6.0 billion for the year, both up 9%. Established Pharmaceuticals, which includes sales of branded generics outside the U.S., declined 5% in the quarter to $1.4 billion and grew 20% to $5.4 billion for the year.